Skip to content

Study · Not a test of the peptide alone · 2007

5 results

Vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase activating peptide (PACAP) receptor specific peptide analogues for PET imaging of breast cancer: In vitro/in vivo evaluation.

Zhang K, Aruva MR, Shanthly N, Cardi CA, Patel CA, Rattan S, Cesarone G, Wickstrom E, Thakur ML

Regulatory peptides6 Jul 2007Cited by 32 (Europe PMC)

PMID17727979 (opens in a new tab)PMCIDPMC2587158 (opens in a new tab)DOI10.1016/j.regpep.2007.06.008 (opens in a new tab)PepBankPUB-17727979
Source linkPubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone5

In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).

  1. 01AnimalNot a test of Vasoactive intestinal peptide (VIP, aviptadil) aloneAnimal study (in vivo)Pharmacokinetics

    Blood clearance of the 64Cu-labelled analogues was rapid, and less than 15% of 64Cu moved to plasma protein in vivo.

    In plain wordsIn animal tests, the labelled analogues cleared quickly from blood, and under 15% of the copper label moved to plasma protein.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    Not applicableBlood clearance and 64Cu transfer to plasma protein
    Study

    n: not reported in source

    Outcome group
    Pharmacokinetics · Pharmacology

    Measurements

    64Cu translocation to plasma protein
    < 15%
    in vivo

    Source sentences

    Summary
    The blood clearance was rapid and in vivo translocation of (64)Cu to plasma protein was <15%.
    2 context sentences
    Title · context
    Vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase activating peptide (PACAP) receptor specific peptide analogues for PET imaging of breast cancer: In vitro/in vivo evaluation.
    Summary · context
    Four potent analogues of these peptides, TP3939, TP3982, TP4200 and TP3805 were labeled with (64)Cu and evaluated ex vivo and in vivo to asses their biological activity and receptor specificity.

    In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).

  2. 02LabNot a test of Vasoactive intestinal peptide (VIP, aviptadil) aloneEx vivo tissueActivity measurement

    The analogues showed receptor affinity 10.93 times greater in human breast cancer tissue than in normal breast tissue.

    In plain wordsIn lab tests on human tissue, the labelled analogues bound 10.93 times more strongly to breast cancer tissue than to normal breast tissue.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    IncreaseReceptor affinity in breast cancer versus normal breast tissue
    Study

    humann: not reported in source

    Human breast cancer and normal breast tissue
    Comparator
    Normal breast tissue
    Outcome group
    Receptor activity and mechanism · Cancer

    Measurements

    Receptor affinity ratio
    10.93 fold
    cancer versus normal breast tissue

    Source sentences

    Summary
    The receptor affinity, using human breast cancer tissues, was 10.93 times greater than normal breast tissues.
    2 context sentences
    Title · context
    Vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase activating peptide (PACAP) receptor specific peptide analogues for PET imaging of breast cancer: In vitro/in vivo evaluation.
    Summary · context
    Four potent analogues of these peptides, TP3939, TP3982, TP4200 and TP3805 were labeled with (64)Cu and evaluated ex vivo and in vivo to asses their biological activity and receptor specificity.

    In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).

  3. 03LabNot a test of Vasoactive intestinal peptide (VIP, aviptadil) aloneEx vivo tissueMechanism

    RT-PCR showed increased VPAC1 receptor expression on human breast tumor cells over normal cells.

    In plain wordsIn lab tests, human breast tumor cells carried more VPAC1 receptor than normal cells.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    IncreaseVPAC1 receptor expression in breast tumor cells
    Study

    humann: not reported in source

    Human breast tumor cells and normal cells
    Comparator
    Normal cells
    Outcome group
    Receptor activity and mechanism · Cancer

    Source sentences

    Summary
    RT-PCR confirmed increased VPAC1 receptor expression on human breast tumor cells over normal cells and corroborated with autoradiography data.
    2 context sentences
    Title · context
    Vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase activating peptide (PACAP) receptor specific peptide analogues for PET imaging of breast cancer: In vitro/in vivo evaluation.
    Summary · context
    Four potent analogues of these peptides, TP3939, TP3982, TP4200 and TP3805 were labeled with (64)Cu and evaluated ex vivo and in vivo to asses their biological activity and receptor specificity.

    In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).

  4. 04LabNot a test of Vasoactive intestinal peptide (VIP, aviptadil) aloneEx vivo tissueActivity measurement

    In a muscle relaxivity assay, the four 64Cu-labelled VIP/PACAP analogues had IC50 values between 8.1x10(-9) M and 8.1x10(-8) M.

    In plain wordsIn lab tests, four labelled VIP-like analogues relaxed muscle tissue at very low concentrations.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    Not applicableMuscle relaxivity IC50 of the analogues
    Study

    n: not reported in source

    Muscle relaxivity assay
    Outcome group
    Receptor activity and mechanism · Cancer

    Source sentences

    Summary
    The muscle relaxivity assay revealed IC(50) to be 5.3x10(-8) M, 4.4x10(-8) M, 8.1x10(-8) M, 8.1x10(-9) M
    1 context sentence
    Summary · context
    Four potent analogues of these peptides, TP3939, TP3982, TP4200 and TP3805 were labeled with (64)Cu and evaluated ex vivo and in vivo to asses their biological activity and receptor specificity.

    In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).

  5. 05LabNot a test of Vasoactive intestinal peptide (VIP, aviptadil) aloneIn vitro (cells)Activity measurement

    In receptor cell binding assays, four 64Cu-labelled VIP/PACAP analogues bound with Kd values of 0.2 to 3.3 nM.

    In plain wordsIn lab tests, four labelled VIP-like analogues bound their receptors tightly, with Kd values between 0.2 and 3.3 nM.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    Not applicableReceptor binding affinity (Kd) of the analogues
    Study

    humann: not reported in source

    Receptor specific cell binding assays
    Outcome group
    Receptor activity and mechanism · Cancer

    Measurements

    Kd
    3.3 nM
    TP3805
    Kd
    0.33 nM
    TP3939
    Kd
    0.2 nM
    TP3982
    Kd
    0.72 nM
    TP4200

    Source sentences

    Summary
    Kd values determined by receptor specific cell binding assays were 3.3 nM, 0.33 nM, 0.2 nM and 0.72 nM for TP3805, TP3939, TP3982, and TP4200 respectively.
    2 context sentences
    Title · context
    Vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase activating peptide (PACAP) receptor specific peptide analogues for PET imaging of breast cancer: In vitro/in vivo evaluation.
    Summary · context
    Four potent analogues of these peptides, TP3939, TP3982, TP4200 and TP3805 were labeled with (64)Cu and evaluated ex vivo and in vivo to asses their biological activity and receptor specificity.

    In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 12:58 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 12:41 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.